

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

CURATIVE BIOTECHNOLOGY, INC.

561-907-8990

curativebiotech.com

ir@curativebiotech.com

SIC – 8731/8733

Quarterly Report

For the Period Ending: September 30, 2021
(the "Reporting Period")

As of November 10, 2021, the number of shares outstanding of our Common Stock was:

544,792,305

As of June 30, 2021, the number of shares outstanding of our Common Stock was:

536,431,194

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

333,000,327

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Curative Biotechnology, Inc., herein referred to as "CUBT" or the "Company."

The company was formerly known as: Connectyx Technologies Holdings Group, Inc., until April 2021, Storage Innovation Technologies, Inc. until 10-07; National Boston Medical, Inc. until 5-04; Fragrance Express, Inc. until 10-98; Growth Industries, Inc. until 7-98

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 31, 2007, was reincorporated in the State of Florida and is active in Florida.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address of the issuer's principal executive office:

1825 NW Corporate Blvd., Suite 110
Boca Raton, FL 33431

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol: CUBT
Exact title and class of securities outstanding: Common Stock
CUSIP: 23128N108
Par or stated value: \$0.0001

Total shares authorized: 1,100,000,000 as of date: 09/30/2021
Total shares outstanding: 544,792,305 as of date: 09/30/2021
Number of shares in the Public Float²: 254,030,181 as of date: 09/30/2021
Total number of shareholders of record: 210 as of date: 09/30/2021

All additional class(es) of publicly traded securities (if any): N/A

Trading symbol: _____
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Issuer Direct Corporation
Address: One Glenwood Ave, Suite 1001
Address 2: Raleigh, NC 27603
Phone: +1 (919) 481-4000
Email: info@issuerdirect.com

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End:

Opening Balance

Date 12/31/18

Common: 322,800,327

Series A Preferred:
34,109,750

Series B Preferred:
293,000

*Right-click the rows below and select "Insert" to add rows as needed.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>3/5/20</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	David Alfred Karram and Sarah Margaret Karram	<u>Web Design and Hosting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>4/28/20</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.0016</u>	<u>No</u>	Pamela Bisikirski and John Bisikirski	<u>Marketing</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Ronald W. Bordens, Ph.D.	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael J. Grace, Ph.D.	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/18/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	I Richard Garr, JD	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/8/20</u>	<u>New Issuance</u>	<u>7,000,000</u>	<u>Common</u>	<u>.013</u>	<u>No</u>	Mid Atlantic BioTherapeutics / David Horn, MD	<u>License Execution</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/8/20</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Michael K. Fish	<u>Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Ronald W. Bordens, Ph.D.	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Michael J. Grace, Ph.D.	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	I Richard Garr, JD	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Dr. Barry A . Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/3/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Ivel Realty Associates Corp / Marc Lewis	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>01/29/21</u>	<u>New Issuance</u>	<u>27,066,666</u>	<u>Common</u>	<u>.0075</u>	<u>No</u>	Green Life, Inc. (Barry A. Ginsberg)	<u>Conversion of Series B Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>1/29/201</u>	<u>Cancelation</u>	<u>203,000</u>	<u>Series B Preferred</u>	<u>N/A</u>	<u>N/A</u>	Green Life, Inc. (Barry A. Ginsberg)			
<u>02/17/21</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Theodore Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>200,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Samuel Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Aaron Charapp	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Ivel Realty Associates (Marc Lewis)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>6,500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exchange Agreement</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Peter and Gail Capuano	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Charles K McHenry	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Josh York	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Joseph Gantz	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	John Acito	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Timothy Sellew	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	SJ Stile Associates, Ltd (Milton Heid)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Theodore Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>2,083,333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Peter and Gail Capuano	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520,833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	GG Capital, LLC (Joseph Gantz)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>416,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Samuel Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/12/21</u>	<u>New Issuance</u>	<u>208,333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	John Acito	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625,000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Aaron Charapp	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625,000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Timothy Sellew	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>208,333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Stile Associates Ltd (Milton Heid)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520,833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Josh York	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520,833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Charles McHenry	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/17/21</u>	<u>New Issuance</u>	<u>400,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Max McKenna	<u>Website Development</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/25/21</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Jose Bardelas	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/26/21</u>	<u>New Issuance</u>	<u>2,083,333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Jose Bardelas	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>2,921,844</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Jeff Frankel	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>3,565,437</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	William Carlson	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643,813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Barry A. Ginsberg	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643,813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Paul Michaels	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>21,931,765</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	SunMed Advisors, LLC (Barry A. Ginsberg) (Paul Michaels)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>3,646,396</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Al Forcella	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/30/21</u>	<u>New Issuance</u>	<u>645,767</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Amanda Schuman	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	293,734	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	David Evrard	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	391,983	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Gary Kabinoff	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	645,709	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Steven Landau	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	253,219	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	MDM Management Corp II (Michael McMeans)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	253,219	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Andrew L Phinney	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>Cancelation</u>	<u>134,109,750</u>	<u>Series A Preferred</u>	<u>N/A</u>	<u>N/A</u>	All Series A Holders	<u>Conversion to Common</u>	<u>N/A</u>	<u>N/A</u>
<u>05/12/2021</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.02</u>	<u>No</u>	Dimiter Dimitrov	<u>Scientific Advisory Board fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/10/2021</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/30/2021</u>	<u>New Issuance</u>	<u>840,000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Margaret McElroy	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/30/2021</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Common</u>	<u>.01</u>	<u>Yes</u>	Adam Drimer	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>7/9/2021</u>	<u>New Issuance</u>	<u>1,200,000</u>	<u>Common</u>	<u>.0075</u>	<u>Yes</u>	Christian Leomporra	<u>Conversion of Series B Shares</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>7/9/21</u>	<u>Cancelation</u>	<u>9,000</u>	<u>Series B Preferred</u>	<u>N/A</u>	<u>N/A</u>	Christian Leomporra			
<u>7/13/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Josh York	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/10/21</u>	<u>New Issuance</u>	<u>1,700,000</u>	<u>Common</u>	<u>.085</u>	<u>No</u>	Fortified Management, LLC (Thomas Scipione)	<u>Settlement Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>

_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
- IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: **Michael K. Fish**
 Title: **Certified Public Accountant**
 Relationship to Issuer: **Director**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

The unaudited financial statements for the period ended 09/30/2021 are attached hereto

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Curative Biotechnologies, Inc. (CUBT) is a development stage biotechnology innovator focusing on novel treatments for rare diseases and therapies with accelerated development paths. At the heart of our process is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease). Our first-generation portfolio under development includes a novel monoclonal antibody drug conjugate to treat newly diagnosed glioblastoma, a novel immunotherapy to treat late-stage rabies, and a reformulated version of the drug Metformin as a topical administration to treat degenerative eye diseases. At Curative Biotech we envision a world where all patients have a therapeutic option.

- B. Please list any subsidiaries, parents, or affiliated companies.

N/A

- C. Describe the issuers' principal products or services.

The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where it's core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company utilizes virtual office space at a cost of \$99 per month.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul M. Michaels	Officer and Director	Boca Raton, FL	<u>47,643,813</u>	Common	9.11%	
			6,000,000	Series C Preferred	20%	
Barry A. Ginsberg, O.D.	Officer and Director	Boca Raton, FL	<u>60,710,479</u>	Common	11.61%	
			6,000,000	Series C Preferred	20%	
Michael K. Fish	Director	Miami, FL	500,000	Common	<1%	
I Richard Garr, J.D.	Officer	Delray Beach, FL	20,250,000	Common	<u>3.87%</u>	
			6,000,000	Series C Preferred	20%	
Ronald W. Bordens, Ph.D.	Officer	Boynton Beach, FL	250,000	Common	<u><1%</u>	
			6,000,000	Series C Preferred	20%	
Michael J. Grace, Ph.D.	Advisor	Hamilton, NJ	250,000	Common	<u><1%</u>	
			6,000,000	Series C Preferred	20%	
Marc Drimer	Director	Boca Raton, FL	1,000,000	Warrants to Purchase Common Stock		Appointed July 14, 2021 Warrants vest as follows: (i) 250,000 shares on July 14, 2021, (ii) 250,000 shares on November 14, 2021, (iii) 250,000 shares on March 14, 2022, and (iv) 250,000 shares on July 14, 2022

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33180
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Michael K. Fish
Firm: Michael K. Fish, CPA PA
Address 1: 7700 N Kendall Dr. #405,
Address 2: Miami, FL 33156
Phone: 305-279-8484

Investor Relations

N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

N/A

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, I Richard Garr, certify that:

1. I have reviewed this quarterly disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 10, 2021 [Date]

/s/ I Richard Garr [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, I Richard Garr, certify that:

1. I have reviewed this quarterly disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 10, 2021 [Date]

/s/ I Richard Garr [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INDEX TO CONDENSED FINANCIAL STATEMENTS

Condensed Balance Sheets	F-2
Condensed Statements of Operations	F-3
Condensed Statements of Deficiency in Stockholders' Equity	F-4
Condensed Statements of Cash Flows	F-6
Notes to Condensed Financial Statements	F-7

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Condensed Balance Sheets

	<u>September 30,</u> 2021	<u>December</u> 31, 2020
ASSETS	(unaudited)	
CURRENT ASSETS		
Cash	\$ 731,844	\$ 160,607
Prepaid expenses	86,010	1,900,859
Amounts receivable on notes payable	<u>-</u>	<u>70,000</u>
Total current assets	<u>817,854</u>	<u>2,131,466</u>
FIXED ASSETS		
Property and equipment	81,515	81,515
Accumulated depreciation	<u>(79,557)</u>	<u>(79,177)</u>
Total Fixed Assets	<u>1,958</u>	<u>2,338</u>
OTHER ASSETS		
Intangible assets, net of amortization	<u>135,425</u>	<u>140,300</u>
Total other assets	<u>135,425</u>	<u>140,300</u>
Total Assets	<u><u>\$ 955,237</u></u>	<u><u>\$ 2,274,104</u></u>
LIABILITIES AND DEFICIENCY IN STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	\$ 255,579	\$ 97,832
Liability to issue common shares	-	7,400
Short term note payable - related parties, net of discounts	-	25,415
Short term convertible note payable - third party	-	128,700
Third party short term loans, net of discounts	<u>-</u>	<u>405,646</u>
Total current liabilities	<u>255,579</u>	<u>664,993</u>
Total Liabilities	<u>255,579</u>	<u>664,993</u>
Commitments and Contingencies		
Preferred Stock, Series A	-	1,564,251
Preferred Stock, Series C	17,087,691	4,566,502
DEFICIENCY IN STOCKHOLDERS' EQUITY		
Preferred stock, \$0.0001 par value, authorized 200,000,000 shares, Series B, 81,000 and 293,000 shares issued and outstanding	8	29
Common stock, \$0.0001 par value, authorized 1,100,000,000 shares; 544,792,305 and 333,000,327 shares issued and outstanding	54,479	33,300
Additional paid-in capital	8,582,715	3,544,657
Accumulated deficit	<u>(25,025,235)</u>	<u>(8,099,628)</u>
Total deficiency in stockholders' equity	<u>(16,388,033)</u>	<u>(4,521,642)</u>
Total Liabilities and Deficiency in Stockholders' Equity	<u><u>\$ 955,237</u></u>	<u><u>\$ 2,274,104</u></u>

The accompanying notes are an integral part of the condensed financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Condensed Statements of Operations
(Unaudited)

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2021	2020	2021	2020
REVENUES, net	\$ -	\$ -	\$ -	\$ -
COST OF REVENUES	-	-	-	-
GROSS MARGIN	-	-	-	-
OPERATING EXPENSES:				
General and administrative expenses	10,275	4,728	37,271	22,660
Payroll and share based compensation	611,839	-	2,964,089	-
Professional fees and share based compensation	116,253	2,980	836,194	45,232
Research and development	125,947	-	221,087	-
Depreciation and amortization	1,990	1,325	4,755	3,976
Impairment of long lived assets	-	-	15,000	-
Total operating expenses	<u>866,304</u>	<u>9,033</u>	<u>4,078,396</u>	<u>71,868</u>
OTHER (INCOME) EXPENSE				
Loss on debt settlement	149,350	-	149,350	-
Interest expense	-	975	176,672	2,925
Total other (income) expense	<u>149,350</u>	<u>975</u>	<u>326,022</u>	<u>2,925</u>
Net (loss) income	<u>\$ (1,015,654)</u>	<u>\$ (10,008)</u>	<u>\$ (4,404,418)</u>	<u>\$ (74,793)</u>
Loss per weighted average common share, basic and diluted	<u>\$0.00</u>	<u>\$0.00</u>	<u>\$(0.01)</u>	<u>\$0.00</u>
Number of weighted average common shares outstanding, basic and diluted	<u>541,061,931</u>	<u>325,550,327</u>	<u>479,104,279</u>	<u>324,615,108</u>

The accompanying notes are an integral part of the condensed financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Condensed Statement of Deficiency in Stockholders' Equity
(Unaudited)

	Number of Shares		Par Value		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred			
BALANCE , January 1, 2020	322,800,327	34,402,750	\$ 32,280	\$3,440	\$ 3,304,187	\$ (3,424,932)	\$ (85,024)
Common shares issued for services	1,500,000	-	150	-	14,850	-	15,000
Net income	-	-	-	-	-	(24,232)	(24,232)
BALANCE , March 31, 2020	324,300,327	34,402,750	32,430	3,440	3,319,037	(3,449,164)	(94,256)
Common shares issued for services	1,250,000	-	125	-	23,175	-	23,300
Net loss	-	-	-	-	-	(43,253)	(43,253)
BALANCE , June 30, 2020	325,550,327	34,402,750	32,555	3,440	3,342,212	(3,492,417)	(114,209)
Net loss	-	-	-	-	-	(10,008)	(10,008)
BALANCE , September 30, 2020	<u>325,550,327</u>	<u>34,402,750</u>	<u>\$ 32,555</u>	<u>\$ 3,440</u>	<u>\$ 3,342,212</u>	<u>\$ (3,502,425)</u>	<u>\$ (124,217)</u>

The accompanying notes are an integral part of the condensed financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Condensed Statement of Deficiency in Stockholders' Equity
(Unaudited)

	Number of Shares		Par Value		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Common	Preferred	Common	Preferred			
BALANCE, January 1, 2021	333,000,327	164,402,750	\$ 33,300	\$29	\$3,544,657	\$ (8,099,628)	\$ (4,521,642)
Series B preferred converted to common	27,066,666	(203,000)	2,707	(20)	(2,686)	-	-
Series A preferred converted to common	135,836,702	(134,109,750)	13,584	-	1,550,667	-	1,564,251
Warrants issued with notes payable	-	-	-	-	9,533	-	9,533
Warrants issued for services	-	-	-	-	40,600	-	40,600
Common shares issued to settle payable	375,000	-	37	--	11,212	-	11,249
Common shares issued for services	6,625,000	-	662	-	329,913	-	330,575
Common shares issued to settle debt	10,937,499	-	1,094	-	655,156	-	656,250
Common shares issued for warrant exercise	10,500,000	-	1,050	-	523,950	-	525,000
Series C preferred stock deemed dividend	-	-	-	-	“*”	(11,615,364)	(11,615,364)
Net loss	-	-	-	-	-	(1,934,499)	(1,934,499)
BALANCE, March 31, 2021	524,341,194	30,090,000	52,434	9	6,663,002	(21,649,491)	(14,934,047)
Common shares issued for cash	10,000,000	-	1,000	-	599,000	-	600,000
Warrants issued for services	-	-	-	-	255,943	-	255,943
Shares issued to settle liability to issue shares	1,000,000	-	100	-	7,300	-	7,400
Common shares issued for services	1,090,000	-	109	-	99,743	-	99,852
Series C preferred stock deemed dividend	-	-	-	-	“*”	(566,946)	(566,946)
Net loss	-	-	-	-	-	(1,454,264)	(1,454,264)
BALANCE, June 30, 2021	536,431,194	30,090,000	53,643	9	7,624,988	(23,670,701)	(15,992,062)
Common shares issued for cash	4,361,111	-	436	-	424,564	-	425,000
Common shares issued for services	800,000	-	80	-	87,670	-	87,750
Series B preferred converted to common	1,200,000	(9,000)	120	(1)	(119)	-	-
Common shares issued to settle debt	2,000,000	-	200	-	179,800	-	180,000
Warrants issued for services	-	-	-	-	47,359	-	47,359
Options issued for services	-	-	-	-	218,454	-	218,454
Series C preferred stock deemed dividend	-	-	-	-	-	(338,880)	(338,880)
Net loss	-	-	-	-	-	(1,015,654)	(1,015,654)
BALANCE, September 30, 2021	<u>544,792,305</u>	<u>30,081,000</u>	<u>\$ 54,479</u>	<u>\$8</u>	<u>\$8,582,716</u>	<u>\$(25,025,235)</u>	<u>\$(16,388,033)</u>

* Series A and C Preferred Stock amounts reflected in mezzanine equity

The accompanying notes are an integral part of the condensed financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Condensed Statements of Cash Flows
(Unaudited)

Nine months ended September 30,

	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net (loss) income	(\$4,404,418)	(\$74,793)
Adjustments to reconcile net loss to net cash used by operating activities:		
Loss on settlement of debt	149,350	-
Depreciation and amortization	4,755	3,976
Share based compensation	2,913,676	30,700
Amortization of Original Issue Discount	122,129	-
Amortization of debt discount	52,593	-
Impairment of long lived assets	15,000	-
Changes in operating assets and liabilities		
Decrease in amounts receivable on notes payable	70,000	-
Increase in prepaid expenses	(86,010)	-
Increase in accounts payable and accrued liabilities	136,712	151
Increase in accrued interest	1,950	2,925
Net cash used in operating activities	(1,024,263)	(37,041)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of intangible assets	(14,500)	-
Net cash used in investing activities	(14,500)	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Cash received for issuance of common stock	1,025,000	-
Cash received upon warrant exercise	525,000	-
Cash received from related party note payable	-	48,083
Repayments of related party notes payable	(50,000)	-
Cash received from third party notes payable	110,000	-
Net cash provided by financing activities	1,610,000	48,083
Net increase in cash	571,237	11,042
CASH, beginning of period	160,607	-
CASH, end of period	\$ 731,844	\$ 11,042
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Interest paid in cash	\$ 10,000	\$ -
Income taxes paid in cash	\$ -	\$ -
Non-cash financing activities:		
Series C preferred stock deemed dividend	\$ 12,521,190	\$ -
Amortization of noncash prepaid expenses	\$ 1,930,877	\$ -
Common shares issued for intangible assets	\$ -	\$ 15,000

The accompanying notes are an integral part of the condensed financial statements

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT) is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Presentation The accompanying unaudited condensed interim financial statements have been prepared in accordance with Generally Accepted Accounting Principles ("GAAP") in the United States of America ("U.S.") as promulgated by the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). In our opinion, the accompanying unaudited interim financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. Certain items have been reclassified to conform with the current presentation.

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Cash and equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit.

(e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments.

FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied.

(k) Stock compensation for services rendered Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the shorter of period the employee or director is required to perform the services in exchange for the award or the vesting period. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes.

Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period.

(n) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the three and nine months ended September 30, 2021 and 2020.

(o) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net loss of approximately \$4.4 million for the nine months ended September 30, 2021 and an accumulated deficit of approximately \$25 million at September 30, 2021. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

NOTE 4 - INTANGIBLE ASSETS

(a) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$22,500, payable one-half in cash and one-half in common stock of the Company. The Company expects to amortize this cost over 3 years once it is operational. This website was placed into service in March 2021. Amortization expense for the nine months ended September 30, 2021 was \$4,375.

(b) Patent rights option In October 2020, the Company entered into an agreement for the option to purchase certain exclusive license rights for US Patent No. 8,287,505 Ophthalmic Drop Dispensing Tip Assembly, issued October 16, 2012, from IEM, Inc., (IEM), the sole owner of this patent. The cost of this option was payment to the US Patent and Trademark Office (US PTO) of the 7.5 year PTO maintenance fee in the amount of \$1,800, which the Company paid in October 2020. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of \$1,000.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 4 - INTANGIBLE ASSETS, continued

(b) Patent rights option, continued

The Company has until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM \$50,000 in exchange for an exclusive world-wide, royalty free perpetual license. The Company is evaluating the Patent rights, potential products and markets under this Patent.

(c) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTherapeutics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immunotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise \$6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A.

The total cost for this license is 20 million shares of the Company's common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at \$91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.

A principal goal of this license is to obtain a Priority Review Voucher (PRV) issued by the US FDA, and subsequently sell the PRV to a major pharmaceutical company. The Company and MABT will split the proceeds from the sale of such PRV equally.

(d) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties.

This license calls for the payment of a non-creditable non-refundable license issue royalty of \$10,000, paid ½ at issuance and ½ on the one year anniversary.

(e) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases.

This license requires two separate royalty streams of payments:

First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of \$8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 4 - INTANGIBLE ASSETS, continued

(e) National Institute of Health (NIH) Patent license #2, continued

Second is an ongoing royalty schedule: an initial royalty of \$5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of \$45,000. There are three benchmark royalties - \$75,000 upon the initiation of the first Phase 2 Clinical Study; \$300,000 upon the completion of Phase 3 Clinical Study and \$600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of \$100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

The patent rights and patent licenses are in the research and development stage, therefore they have not been placed in service and the costs are not being amortized at September 30, 2021.

NOTE 5 - RELATED PARTY TRANSACTIONS

From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction.

During 2020, one officer advanced \$48,083 to the Company, carrying no stated interest rate nor maturity. This advance was repaid during 2020.

At September 30, 2021 and December 31, 2020, two officers of the Company held two of the 4th quarter notes payable totaling \$0 and \$40,000, respectively.

NOTE 6 - NOTES PAYABLE

In January 2021, the amounts receivable for notes payable were received.

During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of \$137,500, including 25% Original Issue Discount (OID), for a total amount of cash received of \$110,000. The notes are identical and carry a maturity of six months from inception and a 25% OID. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. In connection with the notes, the Company issued warrants to purchase 1,100,000 shares of common stock of the Company, which were recorded as a discount in the amount of \$9,533, which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

During 2020, the Company issued thirteen (13) notes payable with a face amount of \$568,750, including 25% OID, for a total amount of cash received of \$455,000. The notes are identical and carry a six month maturity. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. In connection with the notes, the Company issued warrants to purchase 4,550,000 shares of common stock of the Company, which were recorded as a discount in the amount of \$54,554, which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

During the first quarter of 2021, 13 of the 15 note holders converted their notes into shares of common stock at the rate of \$0.06 per share, for a total of 10,937,499 shares of common stock for a total of \$656,250 convertible debt.

During the second quarter of 2021, the remaining two notes, totaling \$40,000 of principal and \$10,000 of OID, were repaid in cash.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 7 - CONVERTIBLE NOTE PAYABLE

In April 2013, the Company entered into a convertible note in the principal amount of \$97,500, which carried a 4% interest rate. This note was convertible at a conversion price equal to the lesser of 90% of the previous 10 day closing price or \$0.001 per share. The balance of the convertible note, including accrued interest, was \$128,700 and \$124,800 at December 31, 2020 and 2019, respectively. Subsequent to December 31, 2020, the note holder filed a lawsuit to enforce the conversion of this note, which was settled in August 2021, via the payment of \$100,000 and the issuance of 2,000,000 shares of common stock valued at \$180,000.

NOTE 8 - LIABILITY TO ISSUE COMMON SHARES

On March 2020, the Company entered into an agreement to issue 1,000,000 shares of common stock in exchange for professional services valued at \$7,400. In June 2021, the Company issued these shares.

NOTE 9 – DEFICIENCY IN STOCKHOLDER’S EQUITY

At September 30, 2021 and December 31, 2020, the Company has 1,100,000,000 shares of par value \$0.0001 common stock authorized and 536,431,194 and 333,000,327 issued and outstanding, respectively. At September 30, 2021 and December 31, 2020, the Company has 200,000,000 shares of \$0.0001 par value preferred stock authorized.

	Series A		Series B		Series C		Total	
	No. Shares	Par	No. Shares	Par	No. Shares	Par	No. Shares	Par
January 1, 2021	134,109,750	\$ 13,411	293,000	\$ 29	30,000,000	\$ 3,000	164,402,750	\$ 16,440
Conversion to common shares	(134,109,750)	(13,411)	(203,000)	(20)	-	-	(134,312,750)	(13,431)
March 31, 2021	-	-	90,000	9	30,000,000	3,000	30,090,000	3,009
	-	-	-	-	-	-	-	-
June 30, 2021	-	-	90,000	9	30,000,000	3,000	30,090,000	3,009
Conversion to common shares	-	-	(9,000)	(1)	-	-	(9,000)	(1)
September 30, 2021	-	\$ -	81,000	\$ 8	30,000,000	\$ 3,000	30,081,000	\$ 3,008

The preferred shares have the following respective rights and privileges:

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating 35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable at the Company’s option for the greater of 45% of the total market value of the common shares or the calculation of the book value of the Company made by an independent audit firm or \$5,000,000. During the first quarter 2021, all of the Series A was converted into 135,836,702 shares of common stock.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

Series B Preferred are convertible in common shares of common stock at a conversion price of \$0.0075 per share; are redeemable at the Company's option at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation.

Series C Preferred are convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry ten votes for each common share that the Series C is convertible into at the record date.

During the third quarter 2021, the Company issued 4,361,111 shares of common stock and 4,361,111 warrants for the purchase of common stock in exchange for \$425,000 in cash. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at \$22,500, to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vest 60,000 immediately, 60,000 in December 2021, 60,000 in April 2022 and 70,000 in August 2022. During the third quarter 2021, the Company issued 300,000 shares of common stock, valued at \$36,720, to an individual for services rendered as a now former member of the Company's Board of Directors. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at \$28,475, to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vested immediately. During the third quarter the Company issued 2,000,000 shares of common stock, valued at \$180,000, to settle the lawsuit brought to enforce the convertible note. During the third quarter 2021, 9,000 shares of the Series B preferred stock was converted into 1,200,000 shares of common stock.

During the second quarter 2021, the Company issued 10,000,000 shares of common stock and 5,000,000 warrants for the purchase of common stock in exchange for \$600,000 in cash. The warrants mature in May 2026, and carry an exercise price of \$0.11 per share. During the second quarter 2021, the Company issued 1,000,000 shares of common stock to settle the liability to issue shares.

During the second quarter 2021, the Company issued 250,000 shares of common stock to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vest 60,000 immediately, 60,000 in August 2021, 60,000 in December 2021 and 70,000 in April 2022. During the second quarter 2021, the Company issued 840,000 shares of common stock to an employee for services to be rendered. These shares vest 210,000 immediately, 210,000 in September 2021, 210,000 in December 2021 and 210,000 in March 2022. 840,000 of these shares to the two (2) individuals were issued and recorded as a prepaid expense to be amortized as they vest.

During the first quarter 2021, the Company issued 125,000 shares of common stock in exchange for services valued at \$5,575, or \$0.0446 per share. During the first quarter 2021, the Company issued 375,000 shares of common stock to settle a payable in the amount of \$11,250. During the first quarter 2021, all of the Series A preferred stock was converted into 135,836,702 shares of common stock. During the first quarter 2021, 203,000 shares of the Series B preferred stock was converted into 27,066,666 shares of common stock. During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of \$0.06 per share, for a total of 10,937,499 shares of common stock for a total of \$656,250 convertible debt. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock for the exercise of 6,500,000 warrants in exchange for services valued at \$325,000.

During the 4th quarter 2020, the Company issued 1,700,000 shares of common stock in exchange for services valued at \$36,800, or \$0.0216 per share. During the 4th quarter 2020, the Company issued 8,500,000 shares of common stock to acquire intangible assets valued at \$106,000, or \$0.0125 per share.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

During the 4th quarter 2020, the Company issued 100,000,000 shares of Series A preferred stock in exchange for services valued at \$1,560,840, or \$0.0156 per share. During the 4th quarter 2020, the Company issued 30,000,000 shares of Series C preferred stock in exchange for services valued at \$4,562,062, or \$0.152 per share. 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which was to be amortized over the remaining of the six month service period.

A deemed dividend for the Series C preferred stock is calculated and recorded upon the issuance of common stock. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was \$11,615,363; \$566,946 and \$338,880, for the first, second third quarters of 2021, respectively.

NOTE 10 - WARRANTS

During the third quarter 2021, the Company issued 4,361,111 warrants for the purchase of common stock of the Company in conjunction with the sale of 4,361,111 shares of common stock for cash. These warrants expire in July and August 2026 and have an exercise price of \$0.15 and \$0.14 per share. During the third quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in July 2024 and have an exercise price of \$0.124 per share and have a cash-less exercise provision. These warrants were recorded at a total value of \$34,382.

During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in conjunction with the sale of 10,000,000 shares of common stock for cash. These warrants expire in May 2026 and have an exercise price of \$0.11 per share. During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in June 2024 and have an exercise price of \$0.20 per share. The warrants were recorded at a total value of \$87,249. During the second quarter 2021, the Company issued 3,000,000 warrants for the purchase of common stock of the Company in exchange for legal services. These warrants expire in May 2026 and have an exercise price of \$0.10 per share. The warrants were recorded at a total value of \$155,717.

During the second quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services. These warrants expire in May 2026 and have an exercise price of \$0.10 per share. The warrants were recorded at a total value of \$51,906 and vest 250,000 shares on May 20, 2021 and September 20, 2021, January 20, 2022 and May 20, 2022. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock in exchange for services valued at \$325,000 for the exercise of 6,500,000 warrants.

In the first quarter 2021, the Company issued 1,100,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately. The warrants were recorded at a total value of \$9,533.

In the first quarter 2021, the Company issued 5,000,000 warrants for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share. The warrants were recorded at a total value of \$40,600.

The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years; stock price between \$0.04 and \$0.10; volatility between 60.51 and 31.56; exercise price between \$0.05 and \$0.2 and bond equivalent yield rate between 0.09% and 0.83%.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 10 - WARRANTS, continued

.During the 4th quarter 2020, the Company issued 4,550,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately. The warrants were recorded at a total value of \$54,555.

During the 4th quarter the Company issued 6,750,000 warrants to two people for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share. The warrants were recorded at a total value of \$44,135.

The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life three years; stock price \$0.03; volatility between 109.96 and 30.22; exercise price \$0.05 and bond equivalent yield rate between 0.08% and 0.11%.

NOTE 11 - OPTIONS

In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1% of the fully diluted issued and outstanding shares upon exercise. These options amounted to 8,081,037 shares at issuance date. These options contain a single recalculation upon the completion of a reverse split of the existing common stock and the Company raising a minimum of \$5 million in an offering. These options carry an exercise price of \$0.11 per share and expire in September 2031. These options were valued at \$436,908 and vest 50% upon issuance and 50% in September 2022.

The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years; stock price \$0.114; volatility 35.13; exercise price \$0.11 and bond equivalent yield rate 1.47%.

NOTE 12- IMPAIRMENT OF LONG LIVED ASSETS

In March 2021, when the Company's new website was placed in service, the remaining unamortized cost of the Company's old website was written off, for a total of \$15,000.

NOTE 13- COMMITMENTS AND CONTINGENCIES

(a) Other The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company's financial position or results of operations.

(b) Litigation In the second quarter 2021, the holder of the short term convertible note filed a lawsuit to enforce the conversion of the note. In August 2021, the Company reached a settlement in which the Company to paid \$100,000 in cash and issued 2,000,000 shares of restricted common stock.

NOTE 14 - CONCENTRATIONS OF CREDIT RISK

(a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had \$477,445 and zero cash balance in excess of FDIC insured limits at September 30, 2021 and December 31, 2020, respectively.

Curative Biotechnology, Inc
(f/k/a Connectyx Technologies Holdings Group, Inc.)
Notes to Condensed Financial Statements
(Unaudited)

NOTE 15 - COVID-19 PANDEMIC

The Company's management is unable to predict the full impact of COVID-19 on the Company.

The corona virus pandemic and subsequent State of Florida ordered shut down did not have a significant effect upon the Company's operations. The Company's access to capital was moderately curtailed, during the pandemic. The Company, as yet, does not know what the ultimate consequences of the pandemic will be upon its business model. Because of COVID-19 and the uncertainty surrounding economic conditions moving forward the Company cannot predict the full impact, although it has had only a moderate impact to date. The Company's staff was already working remotely prior to the onset of the pandemic.

NOTE 16 - SUBSEQUENT EVENTS

(a) Intangible assets In the fourth quarter 2021, the Company entered into a licensing agreement with Mid-Atlantic BioTherapeutics, Inc., (MABT), to license MABT's COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant.

(b) Deficiency in Stockholder's Equity In the fourth quarter 2021, the Company issued 12,500,000 shares of common stock in exchange for MABT COVID-19 licensing agreement. These shares were valued at \$1,425,000.